Recent News

• 02.25.2025 - Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
• 02.25.2025 - Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
• 02.20.2025 - Yigal Nochomovitz, PhD
• 02.20.2025 - Yigal Nochomovitz, PhD
• 02.20.2025 - John Newman, PhD, CFA
• 02.20.2025 - John Newman, PhD, CFA
• 02.13.2025 - H.C. Wainwright @Home Fireside Chat w/ Dr. Paul Peter Tak, CEO Candel Therapeutics
• 02.13.2025 - H.C. Wainwright @Home Fireside Chat w/ Dr. Paul Peter Tak, CEO Candel Therapeutics
• 02.07.2025 - Alec Stranahan, PhD

Recent Filings

• 02.25.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.25.2025 - 8-K Current report
• 02.25.2025 - EX-99.1 EX-99.1
• 02.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.14.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 02.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.14.2025 - 4 Statement of changes in beneficial ownership of securities